Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. No discussions or questions related to raising capital via equity or debt instruments were addressed during the call. The focus was primarily on operational performance, margin guidance, scale-up of the Pune IV plant, and geographic/product portfolio expansion. The company emphasized improving margins, scaling new product lines, and managing working capital internally without indicating external fund-raising plans.

Any current/future capex/capital investment/strategic investment?

The company has recently commissioned a new IV fluid infusion plant in Pune, which started commercial production in December 2025. The Pune plant has an annual installed capacity of 60 million bottles, with ramp-up expected to reach 70% utilization by Q4 FY '27. Expected revenue from the Pune IV plant for FY '27 is around INR 60-65 crores with EBITDA margins of 17-18%. There is ongoing work on dossier filings and approvals for new products, including those for the Pune plant; pipeline approvals were expected by early 2026 but delayed due to regulatory changes. The company is also invested in P

Future growth expectations in sales/revenue/volumes?

FY'27 total revenue guidance: INR 80-85 crores from base business; INR 60-65 crores from Pune IV plant. Base business expected to grow steadily with export operations normalizing and continued expansion in export markets. Injectable segment growth: 10%-12% expected. Tablet segment growth: 7%-8% expected, with increasing product dossiers and portfolio expansion over 2-3 years. Nutraceutical business to ramp up gradually with improved traction in FY'27. Pune IV plant ramp-up: production to increase to 70% utilization by Q4 FY'27, aiming for INR 60 crores annual revenue. Long-term: st

Future growth expectations in earnings/operating earnings/profits/EPS?

For FY'27, base business EBITDA margins are expected in the range of 15.5% to 16.5%, with anticipated recovery from Q1 onwards after March shipment disruptions. The new Pune IV infusion plant aims for an annual revenue of around INR 60-65 crores with EBITDA margins of 17% to 18%, expected to ramp up utilization from 40% in Q1 to 70% in Q4 FY'27. PAT margins will mirror EBITDA margin improvements as higher-margin products enter the portfolio. The nutraceutical venture (Prague-based) is expected to show improved commercial traction and contribute profits in FY'27. Overall, FY'27 is expec

Current/ Expected Orderbook/ Pending Orders?

Pune IV facility currently has 5 product approvals and 18 products in the pipeline. Approval delays have occurred due to government staff transfers and stricter approval processes. A significant portion of approvals (a "quite chunk") is expected to be received in the current month (May 2026). Out of the 18 products in the pipeline for the Pune plant, about 6 are expected to contribute to revenue. Pune IV plant is targeting around INR 60 crore in annual revenue, reflecting a ramp-up and commercial scale-up of new products. The nutraceutical venture (Prague Ventures) is ramping up with a good or

IN US

Sanjiv.Parant.Q1 FY27Pharmaceuticals & Biotechnology

Sanjiv.Parant. Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹203P/E: 35.2Market Cap: ₹235 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

→FY'27 total revenue guidance: INR 80-85 crores from base business; INR 60-65 crores from Pune IV plant.
→Base business expected to grow steadily with export operations normalizing and continued expansion in export markets.
→Injectable segment growth: 10%-12% expected.
→Tablet segment growth: 7%-8% expected, with increasing product dossiers and portfolio expansion over 2-3 years.
→Nutraceutical business to ramp up gradually with improved traction in FY'27.
→Pune IV plant ramp-up: production to increase to 70% utilization by Q4 FY'27, aiming for INR 60 crores annual revenue.
→Long-term: steady increase in injectable and substantial growth in tablets and capsules expected over next 2-3 years.
→Growth impacted recently by geopolitical and logistical challenges, but alternative routes established to support recovery.

Margin guidance

→For FY'27, base business EBITDA margins are expected in the range of 15.5% to 16.5%, with anticipated recovery from Q1 onwards after March shipment disruptions.
→The new Pune IV infusion plant aims for an annual revenue of around INR 60-65 crores with EBITDA margins of 17% to 18%, expected to ramp up utilization from 40% in Q1 to 70% in Q4 FY'27.
→PAT margins will mirror EBITDA margin improvements as higher-margin products enter the portfolio.
→The nutraceutical venture (Prague-based) is expected to show improved commercial traction and contribute profits in FY'27.
→Overall, FY'27 is expected to be stronger with growth and margin expansion driven by all three verticals: base injectable business, IV infusion plant, and nutraceuticals.
→Management remains optimistic about medium to long-term earnings growth fueled by export market expansion and new product approvals.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not mention any current or planned fundraising through debt or equity.
→No discussions or questions related to raising capital via equity or debt instruments were addressed during the call.
→The focus was primarily on operational performance, margin guidance, scale-up of the Pune IV plant, and geographic/product portfolio expansion.
→The company emphasized improving margins, scaling new product lines, and managing working capital internally without indicating external fund-raising plans.

Order book

→Pune IV facility currently has 5 product approvals and 18 products in the pipeline.
→Approval delays have occurred due to government staff transfers and stricter approval processes.
→A significant portion of approvals (a "quite chunk") is expected to be received in the current month (May 2026).
→Out of the 18 products in the pipeline for the Pune plant, about 6 are expected to contribute to revenue.
→Pune IV plant is targeting around INR 60 crore in annual revenue, reflecting a ramp-up and commercial scale-up of new products.
→The nutraceutical venture (Prague Ventures) is ramping up with a good order book in the current year.
→Overall, the company expects stronger momentum with product portfolio expansion and increased commercialization in FY '27.

Capex plans

→The company has recently commissioned a new IV fluid infusion plant in Pune, which started commercial production in December 2025.
→The Pune plant has an annual installed capacity of 60 million bottles, with ramp-up expected to reach 70% utilization by Q4 FY '27.
→Expected revenue from the Pune IV plant for FY '27 is around INR 60-65 crores with EBITDA margins of 17-18%.
→There is ongoing work on dossier filings and approvals for new products, including those for the Pune plant; pipeline approvals were expected by early 2026 but delayed due to regulatory changes.
→The company is also invested in Prague Ventures (nutraceuticals), owning 45% with plans to increase stake to majority in the future; commercial activities and revenue growth expected in FY '27.
→No explicit mention of further large-scale new capex was noted beyond this ongoing plant scale-up and portfolio expansion.

How does Sanjiv.Parant. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sanjiv.Parant.

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sanjiv.Parant.?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio